Tip Cards

The IMF Tip Cards cover key myeloma treatment and care issues in a concise manner and are designed for you to carry with you as consistent references.

What is Multiple Myeloma?
May 16, 2018

Gain a basic understanding of myeloma —what the disease is, its incidence, its symptoms, and how to get support. 


Adherence to Oral Cancer Therapy
September 20, 2016

Studies have demonstrated that lack of adherence to a treatment plan is a major reason for treatment failure

Darzalex® (daratumumab)
April 12, 2017

This laboratory-made monoclonal antibody targets a specific protein on the surface of myeloma cells.


Early Warning Signs
December 01, 2017

Early diagnosis is key to achieving best outcomes for patients

Electronic Medical Records
February 17, 2016

Make certain that all your doctors have equal access to your medical records, no matter which system they use.

Empliciti® (elotuzumab)
April 21, 2017

This immunostimulatory monoclonal antibody is used in combination with lenalidomide + dexamethasone.

Farydak® (panobinostat)
May 17, 2016

This histone deacetylase inhibitor is approved to treat myeloma in combination with bortezomib + dexamethasone.


May 03, 2017

These blood tests measure the concentration of free kappa and free lambda light chains (Freelite®) and the concentration of immunoglobulin pairs (Hevylite®).

Kyprolis® (carfilzomib)
March 16, 2016

This proteasome inhibitor is used in combination with dexamethasone, or with lenalidomide + dexamethasone.


Myeloma and the Immune System
May 16, 2018

Myeloma suppresses the immune system, reducing the number of normal antibodies and affecting all the cells that patrol for and attack abnormal cells.


Myeloma Matrix 2.0: Smart Search
October 09, 2017

The IMF’s Myeloma Matrix, designed to track drugs in development for myeloma, is now Myeloma Matrix 2.0: Smart Search, a clinical trial search tool developed by the IMF and Smart Patients.

Ninlaro® (ixazomib)
June 16, 2016

This proteasome inhibitor is indicated for patients with myeloma who have received at least one prior therapy.


Pomalyst® (pomalidomide)
April 12, 2017

This immunomodulatory drug is indicated in combination with dexamethasone for myeloma patients who have received at least two prior therapies.